A5024625582- Nosocomial Infections in ICU
- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Clostridium difficile and Clostridium perfringens research
- Long-Term Effects of COVID-19
- Hepatitis Viruses Studies and Epidemiology
- Microscopic Colitis
- COVID-19 Impact on Reproduction
- Cytomegalovirus and herpesvirus research
- Drug-Induced Ocular Toxicity
- Surgical site infection prevention
- Bartonella species infections research
- Gallbladder and Bile Duct Disorders
- Bacterial Identification and Susceptibility Testing
- Salivary Gland Disorders and Functions
- Viral Infections and Vectors
- Diverse Scientific Research Studies
- Chronic Lymphocytic Leukemia Research
- Vector-borne infectious diseases
- Systemic Sclerosis and Related Diseases
- Inflammatory Myopathies and Dermatomyositis
- Pancreatic and Hepatic Oncology Research
- Systemic Lupus Erythematosus Research
Universidad de Sevilla
2021-2024
Instituto de Biomedicina de Sevilla
2021-2024
Hospital Universitario de Valme
2021-2024
Junta de Andalucía
2023
The objective of this study was to investigate the efficacy and safety early treatment with sarilumab, added standard care (SOC), in hospitalized adults COVID-19. Methods included phase II, open-label, randomized, controlled clinical trial patients COVID-19 pneumonia interleukin (IL)-6 levels ≥ 40 pg/mL and/or d-dimer > 1,500 ng/mL.
Abstract Background The Clinical Trial of Sarilumab in Adults With COVID-19 (SARICOR) showed that patients with coronavirus disease 2019 (COVID-19) pneumonia and increased levels interleukin (IL)-6 might benefit from blockade the IL-6 pathway. However, this intervention not be uniform. In subanalysis, we sought to determine if other immunoactivation markers, besides IL-6, could identify which subgroup most intervention. Methods SARICOR trial was a phase II, open-label, multicenter,...
ABSTRACT The impact of third-generation cephalosporin-resistant Enterobacterales (3GCR-E) rectal colonization in the development subsequent infection after surgery is controversial. In particular, there a lack data context hepato-pancreato-biliary (HPB) surgery. objective this study was to assess prevalence 3GCR-E intestinal carriage among patients undergoing elective HPB resection and its on incidence etiology surgical site infections (SSIs). This retrospective cohort (January 2016–December...
To investigate the role of previous antibiotic therapy in risk recurrence after a Clostridioides difficile infection (CDI) treated with vancomycin.Multicentre observational study. Patients CDI episode achieving clinical cure oral vancomycin and followed up 8 weeks were included. Previous exposure to 90 days was collected. Multivariate analysis predictors adjusted by propensity score (PS) being previously each non-CDI performed.Two hundred forty-one patients included; 216 (90%) had received...
Abstract Background The aim of this study was to describe the natural history acute Q fever, including its clinical and serological evolution progression chronic fever. Methods Observational cohort (January 2011–September 2020) performed at Valme University Hospital (Seville, Spain). Inclusion criteria: (1) patients aged ≥18 years; (2) fever diagnosis, defined as suggestive symptoms in presence phase II immunoglobulin G (IgG) titer >1:256; (3) least 6 months’ follow-up after episode....
<h3>Background</h3> Optimal hydroxichloroquine (HCQ) dose to reduce ocular toxicity risk is 5 mg/kg or actual weight daily, according new recommendations. In systemic lupus erythematosus patients (SLE) with low no disease activity, fixed low-dose HCQ might be equally effective in relapse prevention weight-adjusted doses, thus resulting lower cumulative dose. <h3>Objectives</h3> Our aim was compare a of 200 mg daily (5 daily) SLE activity. <h3>Methods</h3> activity assessed using the Disease...
<h3>Background</h3> Systemic sclerosis (SSc) is a disorder with well-known autoimmune base. There evidence suggesting common background other connective tissue diseases, thus predisposing to the development of autoimmne disorders in these patients, that is, poliautoimmunity (PAI). <h3>Objectives</h3> To assess PAI cohort SSc patients. <h3>Methods</h3> A nationwide, cross-sectional study was performed including 1928 patients enrolled Spanish Registry (RESCLE). Ethics Committee approval...
<title>Abstract</title> <bold>Objective: </bold>To investigate the impact of COVID19 pandemic on incidence health-care associated <italic>Clostridioides difficile </italic>infection (HA-CDI).<bold>Methods: </bold>Retrospective study conducted in Hospital Universitario de Valme (HUV) and General Alicante (HGUA) Spain between January 2019 February 2021. The period was divided into non-COVID19 (2019 months from 2020-2021 with ≤<bold> </bold>30 hospitalized patients) (months > 30 patients)....
Background and objectives: SARICOR clinical trial (CT) showed that patients with COVID19 pneumonia increased levels of interleukin (IL)-6 might benefit from early blockade IL6-pathway. However, the this intervention not be uniform in all patients. We sought to determine if other biomarkers immunoactivation, besides IL-6, could identify which subgroup most intervention.Methodology: The CT was a phase II, open-label, randomized, multicentre, controlled (July 2020-March 2021) were randomized...